Increased interleukin-17 in the cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease: a case-control study of rapidly progressive dementia by unknown
RESEARCH Open Access
Increased interleukin-17 in the cerebrospinal fluid
in sporadic Creutzfeldt-Jakob disease: a
case-control study of rapidly progressive
dementia
Koji Fujita1*, Naoko Matsui1, Yukitoshi Takahashi2, Yasushi Iwasaki3,4, Mari Yoshida3, Tatsuhiko Yuasa5,
Yuishin Izumi1 and Ryuji Kaji1
Abstract
Background: Inflammatory responses in the cerebrospinal fluid (CSF) of patients with sporadic Creutzfeldt-Jakob
disease (sCJD) remain elusive.
Methods: We conducted a case-control study, in which 14 patients with sCJD, 14 with noninflammatory
neurological disorders, and 14 with autoimmune encephalitis were enrolled. We used the suspension array system to
measure the concentrations of 27 cytokines in CSF. The cytokine titers of the three groups were compared, and the
correlation between the relevant cytokine titers and clinical parameters was investigated in the patients with sCJD.
Results: Levels of the two cytokines interleukin (IL)-1 receptor antagonist and IL-17 were significantly elevated in the
patients with sCJD compared with those in the patients with noninflammatory neurological disorders: IL-17 levels in
sCJD were approximately ten times higher than in the noninflammatory neurological disorders (mean, 35.46 vs.
3.45 pg/ml; P < 0.001) but comparable to that in encephalitis (mean, 32.16 pg/ml). In contrast, levels of
classical proinflammatory cytokines such as IL-12(p70) and tumor necrosis factor-α were increased only in encephalitis.
Although not significant, IL-17 titers tended to be higher in the patients with shorter disease duration before CSF
sampling (r = −0.452; P = 0.104) and in those with lower CSF total protein concentrations (r = −0.473; P = 0.086).
Conclusions: IL-17 is significantly increased in CSF in sCJD, which can be an early event in the pathogenesis of sCJD.
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Background
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive
neurodegenerative disorder belonging to the human prion
diseases and is characterized by the accumulation of prion
or PrPSc [1]. Immunological processes have been poorly
recognized in the central nervous system (CNS) of pa-
tients with CJD, partly because pleocytosis or increased
protein levels are rarely observed in the cerebrospinal fluid
(CSF) of patients with CJD. However, we have detected
antibodies to N-methyl-D-aspartate receptors, typically
present in autoimmune limbic encephalitis [2,3], in CSF of
patients with CJD, which suggests inflammatory or auto-
immune responses in the CNS of patients with CJD.
Cytokines are pivotal factors in CNS inflammation in
autoimmune and neurodegenerative diseases [4]. The
pathogenic activities of cytokines have been vigorously in-
vestigated in prion-infected animal models [5-7]. However,
there is still uncertainty regarding cytokine abnormalities,
particularly in patients with CJD, because some reports
suggest an increase in levels of the proinflammatory cyto-
kines [8,9] while others suggest an increase in levels of the
anti-inflammatory cytokines [10,11] in CSF. Furthermore,
levels of key cytokines in autoimmune and inflammatory
neurological disorders, including interleukin (IL)-17 [12],
have not been evaluated in patients with CJD. We syste-
matically measured levels of multiple proinflammatory
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and anti-inflammatory cytokines in CSF of patients with
CJD to detect CNS inflammatory responses that can be
associated with the pathogenesis of CJD.
Methods
Clinical and neuropathological examination
A case-control study was conducted, and patients admit-
ted to our hospitals from April 2004 to September 2012,
who were diagnosed with sporadic CJD (sCJD) according
to World Health Organization criteria, were recruited
[13]. The prion protein gene (PRNP) was analyzed in the
open reading frame after extracting DNA from the
patients’ blood samples [14,15]. Assays were performed
to assess the CSF γ-isoform of the 14-3-3 protein (cut-
off value, 500 μg/ml) [16] and total tau protein (cut-off
value, 1,300 pg/ml) [17]. With regard to post-mortem
examination, sections from formalin-fixed paraffin-
embedded blocks of the brain were investigated. Mouse
monoclonal antibody 3F4 (Dako, Glostrup, Denmark) and
the EnVision amplified method (EnVision Plus kit; Dako)
after hydrolytic autoclaving of the sections were used to
perform immunohistochemical analysis for PrP [14,18].
Purification and Western blotting of protease-resistant
PrP (PrPSc) from frozen cerebral cortical samples were
performed as described in a previous study [19]. Typing of
PrPSc (type 1 or type 2) was performed according to the
reported classification system [20].
We enrolled age-matched (≥50 years) patients with
noninflammatory neurological disorders as controls and
age-matched patients with noninfectious or autoimmune
encephalitis in whom polymerase chain reaction was
negative for herpes simplex virus-1 and virus-2, varicella-
zoster virus, cytomegalovirus, Epstein-Barr virus and hu-
man herpes virus-6; autoantibodies were not necessarily
screened. This study was approved by the ethics commit-
tee of the Tokushima University Hospital and was per-
formed in accordance with the ethical standards described
in the 1964 Declaration of Helsinki. Written informed
consent was obtained from all participants (or guardians
of participants) in the study. We obtained CSF samples by
lumbar puncture at the time of evaluation from patients
who were undergoing CSF examination as part of their
diagnostic procedure; initial pressure, cell count, total pro-
tein level, and glucose level were measured. Remaining
samples were frozen at −80°C until further investigation.
Cytokine assay
The Bio-Plex Pro Human Cytokine 27-plex assay (M50-
0KCAF0Y; Bio-Rad, Hercules, CA) was used according
to the manufacturer’s instructions to evaluate the con-
centrations of 27 CSF cytokines and chemokines. The 27
cytokines of the panel were IL-1β; IL-1 receptor antag-
onist (IL-1ra); IL-2; IL-4; IL-5; IL-6; IL-7; IL-8/CXCL8;
IL-9; IL-10; IL-12(p70); IL-13; IL-15; IL-17; eotaxin/
CCL1; fibroblast growth factor-2 (FGF-2); granulocyte
colony-stimulating factor (G-CSF); granulocyte macro-
phage colony-stimulating factor (GM-CSF); interferon-γ
(IFN-γ); interferon-inducible protein-10 (IP-10)/CXCL10;
monocyte chemotactic protein-1 (MCP-1)/CCL2; macro-
phage inflammatory protein (MIP)-1α/CCL3; MIP-1β/
CCL4; platelet-derived growth factor BB (PDGF-BB);
regulated on activation, normal T cell expressed and se-
creted (RANTES)/CCL5; tumor necrosis factor-α (TNF-α),
and vascular endothelial growth factor (VEGF).
Statistical analysis
The Kruskal-Wallis test was used to compare the study
groups, followed by Dunn’s multiple comparison post-
hoc analysis. In the multiple comparison analysis,
P values <0.001 were considered to indicate statistical
significance, and P values <0.05 were considered to indi-
cate trends. Spearman’s rank correlation coefficient was
then used to assess the correlations between the cyto-
kine titers and the duration before CSF sampling, the
total protein concentrations, and the total tau protein
titers. In the correlation analysis, P values <0.05 were
considered to indicate statistical significance. GraphPad
Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA)
was used to analyze all the data.
Results
Clinical profiles
We enrolled 14 patients with sCJD (men, 5; age, 73.5±4.9 years
(mean ± standard deviation (SD))): seven with definite and
seven with probable sCJD. PRNP was homozygous for me-
thionine at codon 129 in all the patients. In addition, PrPSc
was type 1 in five patients and type 2 in one patient.
Moreover, the CSF cell count was normal in all the pa-
tients. Furthermore, the CSF 14-3-3 protein was positive
in 12 of 14 patients, and the level of total tau protein was
elevated in 10 of 13 patients (Table 1). The control sub-
jects were 14 patients with noninflammatory neurological
disorders (men, 10; age, 71.8 ± 10.9 years); eight had idio-
pathic normal pressure hydrocephalus, three had parkin-
sonism, two had myalgia/neuralgia and one had constant
headaches. In addition, we enrolled 14 age-matched pa-
tients with noninfectious or autoimmune encephalitis
(men, 8; age, 64.2 ± 7.5 years), including one with gastric
cancer, one with colon cancer, one with prostate cancer,
one with acoustic tumor, one with Hashimoto’s thyroiditis,
one with CNS lupus and schizophrenia, one with anti-
voltage-gated potassium channel complex antibodies-
associated limbic encephalitis, and seven without tumors
or specific autoantibodies.
CSF cytokine profiles
Levels of IL-1ra and IL-17 were significantly higher in
the patients with sCJD than in the controls; the IL-17
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titers in the patients with sCJD were comparable to
those in the patients with encephalitis and approximately
ten times higher than those in the control subjects. The
remaining cytokine levels were not significantly ele-
vated in sCJD, including the classical proinflammatory
cytokines IL-1β and TNF-α and the anti-inflammatory
cytokines IL-4 and IL-10. The elevation of IL-12(p70),
FGF-2, PDGF-BB, and TNF-α levels in the patients
with encephalitis indicated clear contrast with the nor-
mal findings in those with sCJD (Table 2 and Figure 1).
Correlation between interleukin-17 titers and clinical
profiles of Creutzfeldt-Jakob disease
We assessed the relationships between IL-17 titers and the
clinical data of sCJD to investigate how elevated IL-17
levels were associated with disease progression. The IL-17
titers tended to be higher in the patients with shorter dis-
ease duration before CSF sampling (Spearman’s r = −0.452;
P = 0.104), which suggested that levels of IL-17 are in-
creased in the early phases of the disease when neuronal
damage is less severe (Figure 2A). Although not signifi-
cant, the IL-17 titers tended to be higher when the CSF
total protein concentrations were lower (Spearman’s
r = −0.473; P = 0.086; Figure 2B). There was no signifi-
cant correlation between IL-17 titers and total tau pro-
tein titers (Spearman’s r = −0.236; P = 0.485), elevation
of which may reflect the rate of neurodegeneration.
Discussion
In CSF of the patients with sCJD, we detected increases
in IL-17, a cytokine that induces inflammation and can
be pathogenic for autoimmune neurological disorders,
such as multiple sclerosis and experimental auto-
immune encephalomyelitis (EAE) [12,21,22]. It is im-
portant to note that IL-17 is associated with enhanced
neuroinflammation in the absence of PrPC, because
PrPC downregulation can contribute to the pathogen-
esis of prion disease. PrPC-knockout exacerbates and
prolongs neuroinflammation in EAE and is accompan-
ied by an increase in IFN-γ and IL-17 mRNA in CNS
[23]. Moreover, PrPC-knockout can lead to enhanced
EAE severity but with reduction of IL-17-positive Th17
cells [24]. These findings suggest that PrPC downregula-
tion enhances neuroinflammation and IL-17 production,
but that IL-17-producing cells differ from Th17 cells. Be-
sides Th17, IL-17 can be produced by glial cells in CNS
[21], and astrocytes are critical for the IL-17 pathways in
EAE [25,26]. Furthermore, IL-17 can be expressed by
microglia in response to IL-1β or IL-23 [27]. Considering
the rarity of T cells in CNS of patients with CJD, astro-
cytes and microglia can be major sources of IL-17 in CJD.
Increased IL-17 production is a new finding in prion
disease, whereas the activities of other cytokines have
been investigated in prion-infected mice and to a
lesser extent in patients with CJD. Cytokines that are
overexpressed in prion-infected mouse brain include
TNF-α, IL-1α, IL-1β, IL-6, IL-12(p40), transforming
growth factor-β1, MCP-1/CCL2, RANTES/CCL5, CXCL1,
IP-10/CXCL10 and CXCL13 [5-7]. However, CSF find-
ings in patients with CJD remain controversial; early stud-
ies reported an increase in levels of proinflammatory
cytokines TNF-α and IL-1β [8,9], but recent studies
Table 1 Clinical profiles of patients with sporadic Creutzfeldt–Jakob disease
Number Age, sex Diagnosis Codon 129, Cell count (/μl), 14-3-3 Tau Duration before
sampling (months)PrPSc type protein (mg/dl) (μg/ml) (pg/ml)
1 69, M Probable MM 3, 27 + Not performed 1
2 74, F Definite MM 2, 27 + 1275 4
3 76, M Probable MM 6, 60 7313 >2400 2.5
4 70, F Probable MM 5, 43 + 8860 3
5 76, F Probable MM 1, 49 23503 17340 3
6 74, F Probable MM 4, 47 8688 22750 2
7 75, M Probable MM 2, 25 0 0 1
8 83, F Definite MM1 1, 27 2244 10290 6
9 65, F Probable MM 0, 25 1256 3620 8
10 80, M Definite MM1 1, 87 15226 8520 22
11 74, M Definite MM1 1, 30 697 1707 28
12 74, F Definite MM1 2, 27 531 1930 10
13 73, F Definite MM1 1, 35 7188 >13000 4
14 66, F Definite MM2-C 1, 64 0 1180 13
C, cortical type; MM, homozygous for methionine.
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demonstrated normal levels of these classical proinflam-
matory cytokines and increased levels of the anti-
inflammatory cytokines IL-4 and IL-10 [10,11]. In
addition, these studies reported elevated levels of IL-8/
CXCL8 [11], a chemokine that can be associated with
the production of IL-17 in opticospinal multiple sclerosis
[28]. Of these, IL-1 can be pathogenic for prion disease
because IL-1 receptor knockout mice demonstrate sig-
nificantly longer prion-incubation times than controls
[6]. In contrast, IL-10 can be neuroprotective because
IL-10 knockout mice demonstrate significantly shorter
incubation times [6,29]. Conversely, TNF-α, IL-4, IL-6,
IL-12(p40), IL-12(p35), IL-13, and transforming growth
factor-β1 are probably not pathogenic in prion disease
because knockout of these cytokines did not change the
disease course of prion-inoculated mice [5,6,29-31].
Our results were partly consistent with those of recent
reports on human CSF cytokines quantified using
enzyme-linked immunosorbent assay kits that revealed
low titers of IL-1β, IL-6, IL-12, and TNF-α in patients
with CJD [10,11]. However, the significant elevations of
IL-4, IL-10, and IL-8/CXCL8 levels in CJD reported in
these studies [10,11] were not observed in this study.
This inconsistency may result from the different meth-
odologies and disease controls and should be further
investigated in future.
Our results imply that elevated levels of IL-17, a pro-
inflammatory cytokine, can be an early event in sCJD
Table 2 Cytokine profiles in the cerebrospinal fluid
Cytokine (pg/ml) Control CJD Encephalitis P values (vs. Control)
Mean SD Mean SD Mean SD CJD Encephalitis
IL-1β 0.2371 0.2433 0.4871 0.4529 0.1471 0.2015 NS NS
IL-1ra 0 0 18.43 12.38 18.49 13.81 <0.001 <0.001
IL-2 0.6736 1.068 0.7757 1.007 0.1200 0.3007 NS NS
IL-4 0.1800 0.0854 0.5843 0.6772 0.3207 0.3526 NS NS
IL-5 0.4686 0.3360 0.2250 0.3128 0.5514 0.5287 NS NS
IL-6 5.911 1.834 12.36 28.79 14.48 16.42 NS NS
IL-7 0.3593 0.5244 1.196 2.301 0.9507 0.9143 NS NS
IL-8/CXCL8 57.38 14.30 78.63 49.37 130.9 115.9 NS <0.05
IL-9 10.80 2.974 11.06 6.014 34.32 55.89 NS <0.01
IL-10 1.178 0.5076 1.246 1.300 2.871 3.246 NS NS
IL-12(p70) 0.4243 0.5698 1.656 1.790 5.481 8.797 NS <0.001
IL-13 3.204 2.282 2.081 1.845 5.210 7.876 NS NS
IL-15 5.691 4.372 6.366 4.853 20.19 13.01 NS <0.05
IL-17 3.454 7.814 35.46 44.40 32.16 27.14 <0.001 <0.001
Eotaxin/CCL11 0 0 3.236 5.317 3.117 7.441 NS <0.05
FGF-2 7.244 4.743 15.72 12.14 55.16 31.04 NS <0.001
G-CSF 6.539 2.477 10.92 7.283 13.51 8.212 NS <0.05
GM-CSF 339.6 30.78 166.2 103.9 184.7 139.6 <0.01 <0.01
IFN-γ 9.297 3.523 21.33 32.72 17.13 14.67 NS NS
IP-10/CXCL10 1299 342.5 1602 866.9 6140 8906 NS <0.05
MCP-1/CCL2 318.2 118.9 372.7 425.8 357.8 164.2 NS NS
MIP-1α/CCL3 0.7614 0.3028 0.4243 0.8461 2.481 3.056 <0.05 NS
MIP-1β/CCL4 27.38 10.65 31.19 17.70 44.48 24.73 NS NS
PDGF-BB 1.196 3.278 3.638 3.016 16.24 24.69 NS <0.001
RANTES/CCL5 3.168 3.691 4.958 4.583 6.134 5.396 NS NS
TNF-α 6.481 1.837 13.17 10.79 40.68 23.12 NS <0.001
VEGF 12.88 2.234 9.086 6.164 18.51 17.16 NS NS
CJD, Creutzfeldt-Jakob disease; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN-γ, interferon-γ; IL,
interleukin; IL-1ra, IL-1 receptor antagonist; IP-10, interferon-inducible protein-10; MCP-1, monocyte chemotactic protein-1; MIP, macrophage inflammatory protein;
NS, not significant; PDGF-BB, platelet-derived growth factor BB; RANTES, regulated on activation, normal T cell expressed and secreted; SD, standard deviation;
TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.













































































































































































































































































































































































































































































































































































































































Figure 1 Cytokines titers of the multiplex assay. Cytokine titers of the control subjects (n = 14), the patients with sporadic Creutzfeldt-Jakob
disease (CJD, n = 14) and those with autoimmune encephalitis (n = 14). *P < 0.05, **P < 0.01, ***P < 0.001.
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rather than a mere consequence of neurodegeneration
later in the disease course. This observation is intriguing
because the functions of inflammation in the early stages
of pathology have been vigorously investigated in several
neurodegenerative diseases, such as Alzheimer’s disease,
Parkinson’s disease and amyotrophic lateral sclerosis [32].
Moreover, it is worth noting that inflammatory responses
may have dual functions in neurodegeneration, both as in-
stigators of damage and as guardians of brain homeostasis.
Therefore, investigation of the potential activities of IL-17
and other inflammatory markers [33,34] is warranted in
prion disease.
Abbreviations
CJD: Creutzfeldt-Jakob disease; CNS: central nervous system;
CSF: cerebrospinal fluid; EAE: experimental autoimmune encephalomyelitis;
FGF-2: fibroblast growth factor-2; G-CSF: granulocyte colony-stimulating factor;
GM-CSF: granulocyte macrophage colony-stimulating factor; IFN-γ: interferon-γ;
IL: interleukin; IL-1ra: IL-1 receptor antagonist; IP-10: interferon-inducible
protein-10; MCP-1: monocyte chemotactic protein-1; MIP: macrophage
inflammatory protein; PDGF-BB: platelet-derived growth factor BB; PRNP: prion
protein gene; RANTES: regulated on activation, normal T cell expressed and
secreted; sCJD: sporadic Creutzfeldt-Jakob disease; SD: standard deviation;
TNF-α: tumor necrosis factor-α; VEGF: vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KF participated in the design of the study, acquisition and analysis of data,
statistical analysis and manuscript drafting and revision. NM, TY, and RK
participated in data analysis and manuscript revision. YT, Y Iwasaki, and MY
participated in data acquisition and manuscript revision. Y Izumi participated
in acquisition and analysis of data and manuscript revision. All the authors
read and approved the final manuscript.
Acknowledgements
We thank Professor Tetsuyuki Kitamoto (Tohoku University Graduate School
of Medicine) for PRNP analysis and Western blotting and Dr. Katsuya Satoh
(Nagasaki University) for the 14-3-3 protein and total tau protein measurement.
This work was supported by Grants-in-Aid from the Research Committee of
Prion Disease and Slow Virus Infection, the Ministry of Health, Labor and Welfare
of Japan, Health and Labor Sciences Research Grants for Research on Psychiatry
and Neurological Diseases and Mental Health (H20-021) and JSPS KAKENHI
Grant Number 25860715.
Author details
1Department of Clinical Neuroscience, The University of Tokushima Graduate
School, Tokushima 770-8503, Japan. 2National Epilepsy Center, Shizuoka
Institute of Epilepsy and Neurological Disorders, Shizuoka 420-8688, Japan.
3Department of Neuropathology, Institute for Medical Science of Aging, Aichi
Medical University, Nagakute 480-1195, Japan. 4Department of Neurology,
Oyamada Memorial Spa Hospital, Yokkaichi 512-1111, Japan. 5Department of
Neurology, Kamagaya-Chiba Medical Center for Intractable Neurological
Disease, Kamagaya General Hospital, Kamagaya 273-0121, Japan.
Received: 15 September 2013 Accepted: 31 October 2013
Published: 13 November 2013
References
1. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P: Sporadic
human prion diseases: molecular insights and diagnosis. Lancet Neurol
2012, 11:618–628.
2. Fujita K, Yuasa T, Takahashi Y, Tanaka K, Hashiguchi S, Adachi K, Izumi Y,
Kaji R: Detection of anti-glutamate receptor ε2 and anti-N-methyl-D-as-
partate receptor antibodies in a patient with sporadic Creutzfeldt-Jakob
disease. J Neurol 2012, 259:985–988.
3. Fujita K, Yuasa T, Takahashi Y, Tanaka K, Sako W, Koizumi H, Iwasaki Y,
Yoshida M, Izumi Y, Kaji R: Antibodies to N-methyl-D-aspartate glutamate
receptors in Creutzfeldt-Jakob disease patients. J Neuroimmunol 2012,
251:90–93.
4. Lucas SM, Rothwell NJ, Gibson RM: The role of inflammation in CNS injury
and disease. Br J Pharmacol 2006, 147(Suppl 1):232–240.
5. Burwinkel M, Riemer C, Schwarz A, Schultz J, Neidhold S, Bamme T, Baier M:
Role of cytokines and chemokines in prion infections of the central
nervous system. Int J Dev Neurosci 2004, 22:497–505.
6. Tamgüney G, Giles K, Glidden DV, Lessard P, Wille H, Tremblay P, Groth DF,
Yehiely F, Korth C, Moore RC, Tatzelt J, Rubinstein E, Boucheix C, Yang X,
Stanley P, Lisanti MP, Dwek RA, Rudd PM, Moskovitz J, Epstein CJ, Cruz TD,
Kuziel WA, Maeda N, Sap J, Ashe KH, Carlson GA, Tesseur I, Wyss-Coray T,
Mucke L, Weisgraber KH, et al: Genes contributing to prion pathogenesis.
J Gen Virol 2008, 89:1777–1788.
7. Tribouillard-Tanvier D, Striebel JF, Peterson KE, Chesebro B: Analysis of
protein levels of 24 cytokines in scrapie agent-infected brain and glial
cell cultures from mice differing in prion protein expression levels. J Virol
2009, 83:11244–11253.
8. Sharief MK, Green A, Dick JP, Gawler J, Thompson EJ: Heightened
intrathecal release of proinflammatory cytokines in Creutzfeldt-Jakob
disease. Neurology 1999, 52:1289–1291.
9. Van Everbroeck B, Dewulf E, Pals P, Lübke U, Martin JJ, Cras P: The role of
cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob
disease. Neurobiol Aging 2002, 23:59–64.
10. Stoeck K, Bodemer M, Ciesielczyk B, Meissner B, Bartl M, Heinemann U,
Zerr I: Interleukin 4 and interleukin 10 levels are elevated in the
cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
Arch Neurol 2005, 62:1591–1594.

























Figure 2 Correlation of cytokine titers and clinical parameters. (A) Correlation between cerebrospinal fluid interleukin-17 (IL-17) titers and
disease duration before sampling in the patients with sporadic Creutzfeldt-Jakob disease. (B) Correlation between cerebrospinal fluid IL-17 and
total protein titers in the patients with sporadic Creutzfeldt-Jakob disease. Total protein titer was used as a general inflammatory marker in the
central nervous system.
Fujita et al. Journal of Neuroinflammation 2013, 10:135 Page 6 of 7
http://www.jneuroinflammation.com/content/10/1/135
11. Stoeck K, Bodemer M, Zerr I: Pro- and anti-inflammatory cytokines in the
CSF of patients with Creutzfeldt-Jakob disease. J Neuroimmunol 2006,
172:175–181.
12. Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 cells. Annu Rev
Immunol 2009, 27:485–517.
13. World Health Organization: Global Surveillance, Diagnosis and Therapy of
Human Transmissible Spongiform Encephalopathies: Report of a WHO
Consultation. Geneva; 1998.
14. Kitamoto T, Shin RW, Doh-ura K, Tomokane N, Miyazono M, Muramoto T,
Tateishi J: Abnormal isoform of prion proteins accumulates in the synaptic
structures of the central nervous system in patients with Creutzfeldt-Jakob
disease. Am J Pathol 1992, 140:1285–1294.
15. Kitamoto T, Ohta M, Doh-ura K, Hitoshi S, Terao Y, Tateishi J: Novel missense
variants of prion protein in Creutzfeldt-Jakob disease or Gerstmann-
Sträussler syndrome. Biochem Biophys Res Commun 1993, 191:709–714.
16. Satoh K, Tobiume M, Matsui Y, Mutsukura K, Nishida N, Shiga Y, Eguhchi K,
Shirabe S, Sata T: Establishment of a standard 14-3-3 protein assay of
cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease.
Lab Invest 2010, 90:1637–1644.
17. Satoh K, Shirabe S, Eguchi H, Tsujino A, Eguchi K, Satoh A, Tsujihata M,
Niwa M, Katamine S, Kurihara S, Matsuo H: 14-3-3 protein, total tau and
phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-
Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol
2006, 26:45–52.
18. Iwasaki Y, Hashizume Y, Yoshida M, Kitamoto T, Sobue G: Neuropathologic
characteristics of brainstem lesions in sporadic Creutzfeldt-Jakob disease.
Acta Neuropathol 2005, 109:557–566.
19. Shimizu S, Hoshi K, Muramoto T, Homma M, Ironside JW, Kuzuhara S, Sato T,
Yamamoto T, Kitamoto T: Creutzfeldt-Jakob disease with florid-type plaques
after cadaveric dura mater grafting. Arch Neurol 1999, 56:357–362.
20. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I,
Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J,
Vital C, Ghetti B, Gambetti P, Kretzschmar H: Classification of sporadic
Creutzfeldt-Jakob disease based on molecular and phenotypic analysis
of 300 subjects. Ann Neurol 1999, 46:224–233.
21. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L:
Interleukin-17 production in central nervous system-infiltrating T cells
and glial cells is associated with active disease in multiple sclerosis. Am J
Pathol 2008, 172:146–155.
22. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K,
Iwakura Y: IL-17 plays an important role in the development of
experimental autoimmune encephalomyelitis. J Immunol 2006,
177:566–573.
23. Tsutsui S, Hahn JN, Johnson TA, Ali Z, Jirik FR: Absence of the cellular prion
protein exacerbates and prolongs neuroinflammation in experimental
autoimmune encephalomyelitis. Am J Pathol 2008, 173:1029–1041.
24. Ingram RJ, Isaacs JD, Kaur G, Lowther DE, Reynolds CJ, Boyton RJ, Collinge J,
Jackson GS, Altmann DM: A role of cellular prion protein in programming
T-cell cytokine responses in disease. FASEB J 2009, 23:1672–1684.
25. Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W,
Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X: Astrocyte-
restricted ablation of interleukin-17-induced Act1-mediated signaling
ameliorates autoimmune encephalomyelitis. Immunity 2010,
32:414–425.
26. Yan Y, Ding X, Li K, Ciric B, Wu S, Xu H, Gran B, Rostami A, Zhang GX:
CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in
astrocytes. Mol Ther 2012, 20:1338–1348.
27. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H,
Suzumura A: Production and functions of IL-17 in microglia.
J Neuroimmunol 2008, 194:54–61.
28. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M,
Murai H, Mihara F, Taniwaki T, Kira J: Intrathecal activation of the IL-17/IL-8
axis in opticospinal multiple sclerosis. Brain 2005, 128:988–1002.
29. Thackray AM, McKenzie AN, Klein MA, Lauder A, Bujdoso R: Accelerated prion
disease in the absence of interleukin-10. J Virol 2004, 78:13697–13707.
30. Mabbott NA, Williams A, Farquhar CF, Pasparakis M, Kollias G, Bruce ME:
Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient,
mice resist peripheral infection with scrapie. J Virol 2000, 74:3338–3344.
31. Tribouillard-Tanvier D, Race B, Striebel JF, Carroll JA, Phillips K, Chesebro B:
Early cytokine elevation, PrPres deposition, and gliosis in mouse scrapie:
no effect on disease by deletion of cytokine genes IL-12p40 and
IL-12p35. J Virol 2012, 86:10377–10383.
32. Khandelwal PJ, Herman AM, Moussa CE: Inflammation in the early stages
of neurodegenerative pathology. J Neuroimmunol 2011, 238:1–11.
33. Fratini F, Principe S, Puopolo M, Ladogana A, Poleggi A, Piscopo P, Bruno G,
Castrechini S, Pascone R, Confaloni A, Minghetti L, Cardone F, Pocchiari M,
Crescenzi M: Increased levels of acute-phase inflammatory proteins in
plasma of patients with sporadic CJD. Neurology 2012, 79:1012–1018.
34. Chen C, Xiao D, Zhou W, Shi Q, Zhang HF, Zhang J, Tian C, Zhang JZ,
Dong XP: Global protein differential expression profiling of cerebrospinal
fluid samples pooled from Chinese sporadic CJD and non-CJD patients.
Mol Neurobiol 2013: . doi: 10.1007/s12035-013-8519-2.
doi:10.1186/1742-2094-10-135
Cite this article as: Fujita et al.: Increased interleukin-17 in the
cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease: a case-control
study of rapidly progressive dementia. Journal of Neuroinflammation
2013 10:135.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fujita et al. Journal of Neuroinflammation 2013, 10:135 Page 7 of 7
http://www.jneuroinflammation.com/content/10/1/135
